Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G4YR
|
|||
| Former ID |
DIB005294
|
|||
| Drug Name |
MT-3995
|
|||
| Indication | Diabetic nephropathy [ICD-11: GB61.Z; ICD-9: 250.4] | Phase 2 | [1] | |
| Company |
Mitsubishi tanabe pharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Mineralocorticoid receptor (MR) | Target Info | Antagonist | [2] |
| KEGG Pathway | Aldosterone-regulated sodium reabsorption | |||
| Pathwhiz Pathway | Kidney Function | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01756703) A Study to Evaluate Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of MT-3995 in Type II Diabetic Nephropathy Subjects With Albuminuria. U.S. National Institutes of Health. | |||
| REF 2 | Nonsteroidal antagonists of the mineralocorticoid receptor. Curr Opin Nephrol Hypertens. 2015 Sep;24(5):417-24. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.